Share this page!
University Academic Fellow & Hepatologist at University of Leeds. Interested in liver disease and treatment of cirrhosis and HCC. Views my own.
Add to My Authors
21 May 20
Thanks to recent data releases from
I think we can be a little clearer about the excess "non-COVID" mortality in England and Wales
Deaths of Care Home residents in hospital were more likely to be registered as related to COVID than those in care homes
Levels of in hospital mortality in Care Home residents have not substantially increase despite increased illness and overall mortality
Nor do they seem to account for the displacement of in hospital mortality into the community observed by
The displaced in hospital mortality seems for likely to be in deaths at Home which remain high and less frequently attributed to COVID in death registrations
Read 5 tweets
13 May 20
What can patients with
expect from clinical trials?
Recent negative results from $GILD and now $GNFT in Phase 3 highlight the uncertainties entering trials that patients face
Is there a minimum potential benefit a patient should accept when entering a trial?
In Phase 3, participants with
entering a trial there is no certainty that the drug being tested will work and they are taking a risk with a new treatment
Is there a minimum threshold for benefit in a trial that participants might expect?
Earlier today, I asked
what the minimally important difference would be for histologic improvement in phase 3 trials in NASH
The majority thought that at least a 25% absolute improvement in either NASH or fibrosis was the minimum
Read 16 tweets